Legend Biotech director Sanders sells 27,370 shares

Q: How many LEGN shares did director Corazon (Corsee) D. Sanders sell?

Corazon (Corsee) D. Sanders sold 27,370 ordinary shares on September 29, 2026, at a weighted average price of $9.4600 per share. Individual sale prices ranged from $9.445 to $9.48 per ordinary share, and no Rule 10b5-1 plan is reported.

Q: How many LEGN ordinary shares did Corazon (Corsee) D. Sanders hold after the sale?

Sanders held 52,731 ordinary shares following the reported sale.

Legend Biotech ordinary shares may be represented by American Depositary Shares, with each ADS representing two ordinary shares.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Legend Biotech Corp (LEGN) director Corazon (Corsee) D. Sanders sold 27,370 ordinary shares on September 29, 2026, at a weighted average price of $9.4600 per share; individual sale prices ranged from $9.445 to $9.48. The sale was reported as a direct transaction, and no Rule 10b5-1 plan is reported. Sanders held 52,731 ordinary shares following the sale.

Insider Trade Summary

Net Seller: 27,370 shares

Net Sell 1 txn

Insider Sanders Corazon (Corsee) D.

Role Director

Sold 27,370 shs ($259K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares ^{F1, F2}	27,370	$9.46	$259K

Holdings After Transaction: Ordinary Shares — 52,731 shares (Direct)

Footnotes (2)

F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
F2. The price reported in Column 4 is a weighted average price. The prices sold ranged from $9.445 to $9.48 per ordinary share. The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Ordinary shares sold: 27,370 shares Weighted average price: $9.4600 per ordinary share Sale price range: $9.445–$9.48 per ordinary share +2 more

5 metrics

Ordinary shares sold 27,370 shares September 29, 2026

Weighted average price $9.4600 per ordinary share Sale on September 29, 2026

Sale price range $9.445–$9.48 per ordinary share Prices for shares sold

Ordinary shares held after sale 52,731 shares Following the September 29, 2026 sale

Ordinary shares per ADS 2 ordinary shares Each American Depositary Share represents two ordinary shares

Key Terms

weighted average price, American Depositary Shares, Ordinary Shares

3 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

American Depositary Shares financial

"may be represented by American Depositary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Ordinary Shares financial

"The Ordinary Shares of the Issuer"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LEGN shares did director Corazon (Corsee) D. Sanders sell?

Corazon (Corsee) D. Sanders sold 27,370 ordinary shares on September 29, 2026, at a weighted average price of $9.4600 per share. Individual sale prices ranged from $9.445 to $9.48 per ordinary share, and no Rule 10b5-1 plan is reported.

How many LEGN ordinary shares did Corazon (Corsee) D. Sanders hold after the sale?

Sanders held 52,731 ordinary shares following the reported sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/01/2026 - 04:04 PM Accepted by SEC EDGAR 10/01/2026 - 04:04 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sanders Corazon (Corsee) D.

(Last)

(First)

(Middle)

C/O LEGEND BIOTECH CORP

77 CORPORATE DRIVE, 4TH FLOOR

(Street)

BRIDGEWATER

NEW JERSEY

08807

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Legend Biotech Corp [ LEGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares⁽¹⁾	09/29/2026		S		27,370	D	$9.46⁽²⁾	52,731	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

2. The price reported in Column 4 is a weighted average price. The prices sold ranged from $9.445 to $9.48 per ordinary share. The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

	/s/ Robert Staloff, Attorney-in-Fact	10/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR